Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Assembly Biosciences Inc ASMB

Healthcare Biotechnology
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small molecule antiviral therapeutics. The Company’s pipeline includes two helicase-primase inhibitors (HPI) targeting recurrent genital herpes, an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, a clinical-stage capsid assembly modulator (CAM) designed to disrupt the replication cycle... see more

Recent & Breaking News (NDAQ:ASMB)

Assembly Biosciences Announces $30.1 Million Equity Investment and Accelerated Funding from Gilead to Advance Clinical Development Programs

GlobeNewswire 3 days ago

Assembly Biosciences Reports Third Quarter 2024 Financial Results and Recent Updates

GlobeNewswire November 7, 2024

Assembly Biosciences Reports Positive Interim Phase 1a Results from Clinical Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366

GlobeNewswire September 23, 2024

Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates

GlobeNewswire August 8, 2024

Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inhibitors at International Herpesvirus Workshop

GlobeNewswire July 15, 2024

Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 for the Treatment of Chronic Hepatitis B Virus Infection

GlobeNewswire June 18, 2024

Assembly Biosciences Announces $12.6 Million in Equity Financings

GlobeNewswire June 17, 2024

Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus Helicase-Primase Inhibitor Candidate ABI-5366

GlobeNewswire June 10, 2024

Assembly Biosciences Presents New Data Highlighting Hepatitis D Virus Entry Inhibitor ABI-6250 at the EASL Congress(TM) 2024

GlobeNewswire June 5, 2024

Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congress(TM) 2024

GlobeNewswire May 22, 2024

Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights

GlobeNewswire May 8, 2024

Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights

GlobeNewswire March 28, 2024

Assembly Biosciences Announces Effective Date of Reverse Stock Split

GlobeNewswire February 8, 2024

Assembly Biosciences Provides Anticipated Development Milestones for 2024

GlobeNewswire January 4, 2024

Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 10, 2023

Assembly Biosciences Presents New Data Highlighting Viral Hepatitis Portfolio at AASLD The Liver Meeting®

GlobeNewswire November 10, 2023

Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates

GlobeNewswire November 8, 2023

Assembly Biosciences Names Anuj Gaggar, MD, PhD, as Chief Medical Officer

GlobeNewswire November 8, 2023

Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases

Business Wire October 17, 2023

Assembly Biosciences to Present New Data at AASLD The Liver Meeting®

GlobeNewswire October 11, 2023